While AI dominates headlines, GLP-1 drugs could have a more profound and immediate impact on society. They address the core mechanism of desire ("wanting less"), with applications for obesity, addiction, and compulsive behaviors that could fundamentally reshape public health and daily life.

An experiment revealed rats, after tasting a processed "junk food" diet, would rather starve than return to the healthy food they evolved to eat. This shows how the modern food environment alters our brain chemistry to undermine natural satiety, making overconsumption a feature, not a bug.

With 60% of US GDP driven by consumption, a class of drugs that drastically reduces appetite for food—and potentially other goods—poses a direct threat to established economic models. This creates a conflict where what is good for national health (less consumption) is bad for a core metric of national economic success.

Our evolutionary instincts for craving scarce resources haven't adapted to the modern world of abundance. GLP-1 drugs provide a biological support system, or "scaffolding," that helps regulate these outdated cravings for things like high-calorie food and other hedonic activities.

The pressure and guilt mothers feel about nutrition is often misplaced. The root cause is a societal food system that promotes processed, sugary, and addictive foods. This frames the problem as a systemic issue, not an individual moral failing or lack of willpower.

Objecting to GLP-1s for outsourcing discipline is a flawed argument. Medicine has always sought to reduce human struggle, from anesthesia to antibiotics. Viewing GLP-1s as tools that improve biological function to free up human potential for other endeavors is consistent with this history.

While GLP-1 drugs can jumpstart weight loss by reducing appetite, they don't address poor food quality. If users simply eat less ultra-processed food, they risk severe protein and micronutrient deficiencies, leading to different long-term health consequences.

The conversation frames GLP-1 weight-loss drugs not merely as a healthcare breakthrough but as a potential moonshot for the national economy. A mass government rollout could drastically reduce healthcare costs, improve mental health, and boost productivity, representing a powerful tool for social and economic policy with far-reaching ramifications.

While politicians may attack brands like Dunkin' Donuts, the real threat to the fast-food industry comes from GLP-1 drugs like Ozempic. These drugs could fundamentally alter consumer appetite and demand, representing a more direct and powerful disruptive force than any regulation or PR battle.